{
  "id": "fda_guidance_chunk_0354",
  "title": "Introduction - Part 354",
  "text": "and Research in cooperation with the Center for Biologics Evaluation and Research at the Food and Drug Administration. 2 For the purposes of this guidance, all references to drugs include both human drugs and biological products unless otherwise specified. 3 For the purposes of this guidance, adolescents are defined as 12 years of age to younger than 18 years of age. 4 For treatment trials, sponsors should document diagnosis of laboratory-confirmed SARS-CoV-2, as well as the duration of symptoms before treatment. Sponsors of clinical trials to evaluate drugs and biological products to treat or prevent COVID-19 should see the guidance for industry, investigators, and institutional review boards Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due To Disasters and Public Health Emergencies (September 2023) and the guidance for industry COVID-19: Developing Drugs and Biological Products for Treatment or Prevention (November 2023). We update guidances periodically. For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/regulatory-information/search-fda-guidance-documents. Contains Nonbinding Recommendations and (g)(3). FDA made this determination because although the COVID-19-related public health 31 emergency under section 319 of the Public Health Services Act has expired, SARS-CoV-2 32 continues to circulate, COVID-19 remains a serious health risk for some individuals, and there is 33 a need to ensure that sponsors are aware of FDA’s recommendations to facilitate timely 34 development of drugs and biological products for treatment and prevention of COVID-19. This 35 guidance supersedes the guidance of the same name issued on September 29, 2020. 36 In general, FDA’s guidance documents do not establish legally enforceable responsibilities. 38 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only 39 as recommendations, unless specific regulatory or statutory requirements are cited. The use of 40 the word should in Agency guidance means that something is suggested or recommended, but 41 not required. 42 II. BACKGROUND 45 Sponsors continue to conduct outpatient prevention or treatment clinical trials in adult and 47 adolescent subjects that incorporate assessments of COVID-19-related symptoms; however, 48 challenges persist. These challenges include but are not limited to the identification of methods 49 to assess the numerous and heterogenous symptoms across subjects, patient burden, poor 50 compliance with diary completion, and potential missing data. To address these challenges, 51 sponsors",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 474432,
  "end_pos": 475968,
  "tokens": 512,
  "tags": [
    "safety",
    "regulatory",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.704Z"
}